Follow DNDi on LinkedInFollow DNDi on TwitterFollow DNDi on Facebook
Connect to Fight Neglect! To celebrate our 10-year anniversary, we have create a website dedicated to the voices of all actors in neglected disease R&D.

Over 1 billion people, including 500 million children, in the poorest regions of the world, are affected by neglected diseases that debilitate, disfigure or kill.

DNDi’s research and development approach is driven by the real day-to-day needs of patients and healthcare providers.

By connecting public and private partners, DNDi synergizes expertise and capitalizes upon the best science. 

DNDi also works to strengthen the health R&D field in the countries where the diseases occur in order to reinforce capacities for sustainable change.

Major progress has been made in the short-term with six new treatments made available to forgotten patients since the creation of DNDi, in 2003.

However, major breakthroughs are still needed to treat patients: Entirely new, affordable, and adapted drugs will change the lives of millions of people.

SPOTLIGHT
«
»

In pictures: filaria in Ghana

Filarial diseases devastate the lives of patients, causing debilitating symptoms and social discrimination. DNDi traveled to rural Ghana to meet and interview patients with filaria and the physician-researchers treating them. More

Pilot Pooled Fund for R&D

This recent paper commissioned by DNDi examines the possibilities of creating a pooled international R&D fund for the Demonstration Projects selected as part of the process following on the report of the WHO Consultative Expert Working Group on R&D (CEWG). More

AN ALTERNATIVE R&D MODEL

To mark its 10 year anniversary, DNDi has issued a report that explores the lessons learned from a decade of R&D of new treatments for neglected diseases via a cost-effective, innovative, not-for-profit drug development model. More

CHAGAS DISEASE

The soccer star Lionel Messi, having seen the Ricardo Preve documentary 'Chagas, A Silent Killer', speaks out about Chagas disease and calls for teamwork to treat patients and find altogether new treatments. More

SLEEPING SICKNESS

Fexinidazole: launch of Phase II/III clinical trial in the Democratic Republic of Congo and Central African Republic.The study, initiated by DNDi and its partners, will test the efficacy and safety of fexinidazole, with once daily tablets for ten days. More

PAEDIATRIC HIV

Testimonies of South African mothers: demonstrating the difficulties in administering current treatments for paediatric HIV More

LEISHMANIASIS

Voices for neglected diseases. Lemarus Tebakwani Lukeno has been treated with SSG&PM for kala-azar; read his and other patient stories More

MALARIA

280 million treatments of ASAQ, DNDi’s antimalarial combination therapy of Artesunate and Amodiaquine, have been distributed in over 30 countries since its launch in 2007! More

DNDi NEWS

   

July 20 - 25, 2014
AIDS 2014
20th International AIDS Conference (IAC)
Melbourne, Australia
DNDi is co-hosting a satellite event on paediatric HIV.

August 10-15, 2014
ICOPA
13th International Congress of Parasitology
Mexico City, Mexico
DNDi is presenting and participating in symposia and satellite meetings at ICOPA.

August 24 - 28, 2014
35th Annual Conference of the International Society for Clinical Biostatistics
Vienna, Austria
DNDi is presenting a poster on clinical trials for visceral leishmaniasis.

See all events

DNDi WORLDWIDE

REPORT: 10 YEARS OF DNDi

DNDi Model Paper
DNDi has issued a report that explores the lessons learned from a decade of R&D of new treatments for neglected diseases via a cost-effective, innovative, not-for-profit drug development model. Read more

TWITTER

Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site
is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License